Rasmussen J E
J Am Acad Dermatol. 1981 Nov;5(5):507-16. doi: 10.1016/s0190-9622(81)70110-5.
The human clinical use of 1% lindane formulations has become somewhat controversial during the past five years. This review is an in-depth report of the efficacy and safety of 1% lindane compared with the agents that have been preferred as alternative. Almost all of the suspected adverse drug reactions (ADR) from 1% lindane have involved substantial misuse. The number of suspected ADRs remains small, especially when compared with the magnitude of human clinical use of 1% lindane preparations in the United States (50 million ounces during the past five years). One percent lindane should continue to remain the preparation of choice for nearly all patients with scabies and lice, but dermatologists should appreciate that these views are not necessarily shared by all health professionals. Consequently, it is most appropriate to explain the possible side effects from misuse of lindane to each patient. This brief period of patient education is time well spent--it will help maintain proper compliance and allay the upset that many of your patients may have if they encounter negative opinions about lindane in the lay and medical press or from other health professionals.
在过去五年中,1%林丹制剂在人类临床应用方面已颇具争议。本综述是一份关于1%林丹与其他首选替代药物相比的疗效和安全性的深入报告。几乎所有疑似由1%林丹引起的药物不良反应(ADR)都涉及严重的误用情况。疑似ADR的数量仍然较少,尤其是与美国1%林丹制剂的人类临床使用规模相比(过去五年中达5000万盎司)。对于几乎所有疥疮和虱子患者而言,1%林丹仍应继续作为首选制剂,但皮肤科医生应认识到,并非所有医疗专业人员都认同这些观点。因此,向每位患者解释林丹误用可能产生的副作用是最为恰当的。这段简短的患者教育时间很值得花费——它将有助于维持患者的正确依从性,并减轻许多患者在大众媒体、医学刊物或其他医疗专业人员那里遇到关于林丹的负面评价时可能产生的不安情绪。